46亿估值！高瓴投出一家创新药IPO，手握“聪明药”，来自上海浦东

Core Viewpoint - The article discusses the IPO of an innovative drug company backed by Hillhouse Capital, which has a valuation of 4.6 billion and specializes in "smart drugs" [1] Group 1: Company Overview - The company is based in Shanghai Pudong and focuses on the development of innovative pharmaceuticals [1] - It has gained attention for its unique approach to drug development, particularly in the area of cognitive enhancement [1] Group 2: Investment Highlights - Hillhouse Capital's investment indicates strong confidence in the company's potential and market position [1] - The valuation of 4.6 billion reflects the growing interest and demand for innovative healthcare solutions in the market [1]